DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA

被引：0
|
作者：
Matas-Cespedes, A. [1 ]
Vidal-Crespo, A. [1 ]
Rodriguez, V. [1 ]
Rossi, C. [2 ]
Roue, G. [1 ]
Lopez-Guillermo, A. [3 ]
Gine, E. [3 ]
Wiestner, A. [4 ]
Bezombes, C. [2 ]
Campo, E. [5 ]
Colomer, D. [5 ]
Balasubramanian, S. [6 ]
Chiu, C. [6 ]
Doshi, P. [6 ]
Perez-Galan, P. [1 ]
机构：
[1] IDIBAPS, Hematol Oncol, Barcelona, Spain
[2] CRCT, Hematol Oncol, Toulouse, France
[3] Hosp Clin Barcelona, Hematol, Barcelona, Spain
[4] NIH, Hematol, Bldg 10, Bethesda, MD 20892 USA
[5] Hosp Clin Barcelona, Pathol, Barcelona, Spain
[6] Janssen, R&D, Spring House, PA USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1369
引用
收藏
页码：563 / 563
页数：1
相关论文
共 50 条
  • [31] Antibody therapy for non-Hodgkin's B-cell lymphoma proves itself
    Clark, M
    LANCET, 1997, 349 (9044): : 34 - 34
  • [32] Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
    Liu, Yang
    Li, Yanju
    Zhang, Chike
    Yang, Xu
    Yang, Bo
    Cheng, Jinyang
    Chen, Juan
    Yuan, Xiaoshuang
    Li, Ya
    Chen, Ying
    Zhang, Fengqi
    Tang, Dongxin
    He, Zhixu
    Wang, Feiqing
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [33] New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma
    Burton, Jack D.
    Goldenberg, David M.
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (04) : 569 - 583
  • [34] Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
    Yang Liu
    Yanju Li
    Chike Zhang
    Xu Yang
    Bo Yang
    Jinyang Cheng
    Juan Chen
    Xiaoshuang Yuan
    Ya Li
    Ying Chen
    Fengqi Zhang
    Dongxin Tang
    Zhixu He
    Feiqing Wang
    Discover Oncology, 15
  • [35] Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma
    Kunkel, LA
    CANCER INVESTIGATION, 2004, 22 (01) : 97 - 105
  • [36] Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
    Novakovic, Barbara Jezersek
    Boltezar, Lucka
    Novakovic, Aleksander
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 183 - 192
  • [37] Traditional treatment approaches in B-cell non-Hodgkin's lymphoma
    Zinzani, PL
    LEUKEMIA & LYMPHOMA, 2003, 44 : S6 - S14
  • [38] Aberrant Expression of CD8 in B-Cell Non-Hodgkin Lymphoma
    Carulli, Giovanni
    Stacchini, Alessandra
    Marini, Alessandra
    Ciriello, Maria Matilde
    Zucca, Alessandra
    Cannizzo, Elisa
    Aliberti, Sabrina
    Demurtas, Anna
    Novero, Domenico
    Calcagno, Lara
    Callegari, Tiziana
    Petrini, Mario
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (02) : 186 - 190
  • [39] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [40] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
12345